ATE424209T1 - Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung - Google Patents

Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung

Info

Publication number
ATE424209T1
ATE424209T1 AT03782745T AT03782745T ATE424209T1 AT E424209 T1 ATE424209 T1 AT E424209T1 AT 03782745 T AT03782745 T AT 03782745T AT 03782745 T AT03782745 T AT 03782745T AT E424209 T1 ATE424209 T1 AT E424209T1
Authority
AT
Austria
Prior art keywords
gnrh
luteal phase
support
phase during
gnrh agonists
Prior art date
Application number
AT03782745T
Other languages
English (en)
Inventor
Ernest Loumaye
Original Assignee
Preglem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Preglem Sa filed Critical Preglem Sa
Application granted granted Critical
Publication of ATE424209T1 publication Critical patent/ATE424209T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2093—Leukaemia inhibitory factor [LIF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Reproductive Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03782745T 2002-12-27 2003-12-29 Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung ATE424209T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0216810A FR2849380A1 (fr) 2002-12-27 2002-12-27 NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US44846803P 2003-02-21 2003-02-21

Publications (1)

Publication Number Publication Date
ATE424209T1 true ATE424209T1 (de) 2009-03-15

Family

ID=32683902

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03782745T ATE424209T1 (de) 2002-12-27 2003-12-29 Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung

Country Status (9)

Country Link
US (1) US7671027B2 (de)
EP (1) EP1578427B1 (de)
AT (1) ATE424209T1 (de)
AU (1) AU2003290383A1 (de)
DE (1) DE60326490D1 (de)
DK (1) DK1578427T3 (de)
ES (1) ES2323693T3 (de)
FR (1) FR2849380A1 (de)
WO (1) WO2004058269A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0307777D0 (en) 2003-04-04 2003-05-07 Medical Res Council Conjugate compounds
JP2009510090A (ja) 2005-09-27 2009-03-12 ミリアド ジェネティックス インコーポレーティッド 治療化合物としてのピロール誘導体
US20150273020A1 (en) * 2007-05-11 2015-10-01 Lori R. Bernstein Hormone Normalization Therapy and Uses Therefor
PL2359807T3 (pl) 2008-02-04 2017-12-29 Ferring B.V. Monolityczne pierścienie dopochwowe zawierające progesteron oraz metody ich wytwarzania i stosowania
FR2942409B1 (fr) * 2009-02-20 2013-07-26 Natacha Voillot Composition pharmaceutique pour la prevention des avortements a repetition.
WO2010130008A1 (en) * 2009-05-14 2010-11-18 Adelaide Research & Innovation Pty Ltd Methods for the collection and maturation of oocytes
WO2011076117A1 (zh) 2009-12-22 2011-06-30 上海天伟生物制药有限公司 绝经期促性腺素组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US8633178B2 (en) 2011-11-23 2014-01-21 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9216037B2 (en) 2013-06-21 2015-12-22 Previvo Genetics, Llc Uterine lavage for embryo retrieval
US20150272622A1 (en) 2011-12-22 2015-10-01 Previvo Genetics, Llc Recovery and processing of human embryos formed in vivo
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
EP3145489A1 (de) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Natürliche kombinierte hormonersatzformulierungen und therapien
RU2016141135A (ru) 2014-07-29 2018-08-28 Терапьютиксмд, Инк. Трансдермальный крем
EP3037101B1 (de) * 2014-12-22 2019-03-06 Ferring B.V. Oxytocinrezeptorantagonistentherapie in der Lutealphase für Implantation und Schwangerschaft bei mit Technologien zur unterstützten Fortpflanzung behandelten Frauen
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP6905714B2 (ja) * 2015-09-17 2021-07-21 学校法人東京農業大学 始原生殖細胞を機能的に成熟した卵母細胞へと分化させる培養方法
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
WO2017173071A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
CN112352045B (zh) * 2018-06-21 2023-10-20 国立大学法人九州大学 在体外将原始生殖细胞分化为原始卵泡的方法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5538948A (en) * 1987-01-30 1996-07-23 Novo Nordisk A/S Method for treating infertility comprising administering GnRH analog, gonadotrophins, and growth hormone
US6489288B1 (en) * 1990-03-16 2002-12-03 Applied Research Systems Ars Holding Treatment of polycystic ovarian disease
FR2713933B1 (fr) * 1993-12-16 1996-02-02 Rhone Merieux Méthode de superovulation des femelles bovines, méthode de mise en anoestrus et kit approprié.

Also Published As

Publication number Publication date
EP1578427A1 (de) 2005-09-28
DK1578427T3 (da) 2009-06-29
EP1578427B1 (de) 2009-03-04
WO2004058269A9 (en) 2004-09-23
DE60326490D1 (de) 2009-04-16
US7671027B2 (en) 2010-03-02
ES2323693T3 (es) 2009-07-23
AU2003290383A1 (en) 2004-07-22
US20060069031A1 (en) 2006-03-30
FR2849380A1 (fr) 2004-07-02
WO2004058269A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
ATE424209T1 (de) Verwendung von gnrh-agonisten zur unterstützung der lutealphase während einer unfruchtbarkeitsbehandlung
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
EA200200208A1 (ru) Синергитическая композиция
BRPI0418029A (pt) formulação de anticorpos cd40 e métodos
DK0462189T3 (da) Kombinationsterapi til behandling af østrogenfølsomme sygdomme
DE69027865D1 (de) ZUSAMMENSETZUNGEN enthaltend omega Conotoxin Peptide Derivate und deren Verwendung ZUR BEHANDLUNG VON ISCHÄMIE-ARTIGEN NEURONALEN SCHÄDIGUNGEN
EA200501548A1 (ru) Ингибиторы фосфодиэстераз при бесплодии
AR005987A1 (es) Terapia combinada para la osteoporosis
DE60324431D1 (de) Derivate des 3-hydroxy-4-(cyclyl-alkylaminoalkyl)-5-phenyl-1h-pyrazols als antagonisten des gonadotropin freisetzenden hormons (gnrh) zur anwendung in de behandlung von geschlechtshormonellen erkrankungen, wie prostata- oder gebahrmutterkrebs
DE60112301D1 (de) Verwendung von (deaminohydroxy)toremifene zur behandlung von vaginalen trockenheit oder sexuellen störung während und nach der menopause
JP2003528919A5 (de)
BG101126A (en) The use of muramylpeptide compounds
PE20050665A1 (es) ESTROGENOS SELECTIVOS DE 8ß-VINIL-ESTRA-1,3,5(10)-TRIEN-3,17ß-DIOL Y 17ß-FLUOR-9-VINIL-ESTRA-1,3,6(10)-TRIEN-3,16ALFA-DIOL
BG101158A (bg) Използване на антагонист на gnrh за получаване нафармацевтичен състав за лечение на гонадостероидно зависими заболявания
Fu et al. Dynamic alterations in the expression and localization of ACTL7a during capacitation in mouse spermatozoa
EA200200943A1 (ru) Гормональная терапия рака молочной железы
DE60045555D1 (de) Apparat zur verringerung des embolierisikos während der behandlung von erkrankungen der kopfschlagader
NO830041L (no) Fremgangsmaate til behandling av azykli hos sauer eller storfe
DK1509215T3 (da) Behandling eller forebyggelse af urogenital atrofi og dets symptomer hos kvinder
ATE440601T1 (de) Hydroxypyridinone zur lokalen behandlung von hautmikrozirulationsstírungen
BR0111546A (pt) Produto combinado, método para a produção de um kit de partes, kit de partes, método de tratamento de uma condição, usos de um produto combinado ou de um kit de partes, e, de um melagatrano e de um inibidor de fator viia, ou de um derivado farmaceuticamente aceitável dos mesmos
DK384086D0 (da) Antigestagener til forskydning af den endometriale modning
FI982198A0 (fi) IL-muteiini
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin
UY27115A1 (es) Uso de gestágenos para inhibir la maduración acelerada del endometrio durante el tratamiento de la infertilidad

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1578427

Country of ref document: EP